EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial

Samantha V Abram, Juliette M Kyner, An Vu, Zanib Naeem, Shebani Sethi, Michael S Jacob iD, Susanna L Fryer, Daniel H Mathalon, Judith M Ford iD

Schizophrenia Bulletin · 03.07.2026 · 52 (4)

DOI: 10.1093/schbul/sbag082 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Bulletin, online erschienen am 08.07.2026. Verfasst von Samantha V Abram und 8 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Services, San Francisco VA Medical Center, 4150 Clement St, San Francisco, CA 94121, United States. Hauptthemen laut MEDLINE: Bipolar Disorder, Cognitive Dysfunction, Diet, Ketogenic, Insulin Resistance. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Mental Health, Baszucki Group, VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis Psychiatric medications contribute to high rates of metabolic dysfunction in psychotic disorders. Ketogenic diets reduce metabolic syndrome, have anticonvulsant effects in epilepsy, and may improve symptoms of schizophrenia and bipolar disorder. We report the first randomized controlled trial to assess effects of ketogenic diets on metabolism, psychiatric symptoms, and cognition in people with schizophrenia-spectrum and bipolar-1 disorders. Study Methods Participants were randomized to a ketogenic diet (KETO; n = 28) or diet-as-usual (DAU; n = 30) for 1 month. Partway through the trial, a KETO extension was offered to both groups, resulting in a sub-group who completed the diet for 4 months (n = 25). We assessed changes in metabolic health, clinical symptoms, and cognition after 1 month (KETO versus DAU) and after 4 months (KETO versus baseline). Study Results KETO participants’ daily ketone levels surpassed the standard ketosis threshold. Relative to DAU, KETO participants showed reductions in weight (Padj < .001), hemoglobin A1c (Padj = .05), and insulin resistance (Padj = .05). Clinical symptoms (positive, negative, depression) and cognitive performance improved after 4 months on the KETO (all P-values < .001). Increased blood ketone levels in KETO participants correlated with improvements in pre-diabetic markers and depressive symptoms (all P-values < .001). Reduced weight following the KETO was unrelated to metabolic and symptom improvements. Conclusions We demonstrate feasibility of administering a KETO in outpatients with schizophrenia and bipolar-1 disorder. Participants showed improvement in metabolic health, cognitive performance, and clinical symptoms. Improvement in depressive symptoms was associated with ketosis rather than weight loss, implicating ketosis as the therapeutic mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderCognitive DysfunctionDiet, KetogenicInsulin ResistanceOutcome Assessment, Health CarePsychotic DisordersSchizophreniaAdultFemaleHumansMaleMiddle AgedYoung Adult

Stichwörter der Autor:innen

bipolar disorderdepressive symptomsketogenic dietmetabolismneuropsychological testingpsychosis symptomsrandomized controlled trialschizophrenia

Autor:innen und Institutionen

  • Mental Health Services, San Francisco VA Medical Center, 4150 Clement St, San Francisco, CA 94121, United States.
  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94143, United States.
  • Northern California Institute for Research and Education, San Francisco, CA 94121, United States.
  • Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, United States.

ORCID-Profile: Michael S Jacob, Judith M Ford

Förderung

  • National Institutes of Mental Health
  • Baszucki Group
  • VA
  • Career Development Awards
  • Department of Veterans Affairs

Zitieren

APA

Abram, S. V., Kyner, J. M., Vu, A., Naeem, Z., Sethi, S., Jacob, M. S., Fryer, S. L., Mathalon, D. H., & Ford, J. M. (2026). Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial. Schizophrenia Bulletin, 52(4). https://doi.org/10.1093/schbul/sbag082

Vancouver

Abram SV, Kyner JM, Vu A, Naeem Z, Sethi S, Jacob MS, et al. Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial. Schizophrenia Bulletin. 2026;52(4). doi:10.1093/schbul/sbag082

BibTeX
@article{Abram2026,
  author = {Abram, Samantha V and Kyner, Juliette M and Vu, An and Naeem, Zanib and Sethi, Shebani and Jacob, Michael S and Fryer, Susanna L and Mathalon, Daniel H and Ford, Judith M},
  title = {Metabolic Improvements with a Ketogenic Diet Correlate with Symptom Improvement in Psychosis: A Randomized Controlled Trial},
  journal = {Schizophrenia Bulletin},
  year = {2026},
  volume = {52},
  number = {4},
  doi = {10.1093/schbul/sbag082}
}
Kostenlos starten →